Please assess the completion status of the following clinical trial:

Trial Title: Optimization of Therapeutic Human Serum Albumin Infusion in Selected Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* circulatory failure requiring norepinephrine support (any dose)~* hospitalization within an Intensive Care Unit~* SIRS~* low plasma albumin (\< 20g/L)~* consent to study~Exclusion Criteria:~* absence of circulatory failure~* absence of SIRS~* chronic low albumin concentration~* absence of consent to study~* inability to tolerate human serum albumin~* Patients under guardianship or curators~* Women pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous low dosage (CLD) (Type: EXPERIMENTAL): The subjects will received human serum albumin infusion 4%.CLD patients are infused with15ml/kg/day of 4% human serum albumin from inclusion to the day norepinephrine infusion is weaned by 30% (provided their plasma albumin stays in the range 30+3g/L)
- Intermittent high dosage (IHD) (Type: ACTIVE_COMPARATOR): The subjects will received human serum albumin infusion 20%.IHD patients are infused with 20% human serum albumin (up to 600 ml/day) until the plasma albumin concentration is in the range 30+3g/L from inclusion to the day norepinephrine infusion is weaned by 30%

Based on this trial design, predict the completion outcome and termination type (if applicable).